Phase II Clinical Trial of Recombinant Human Interleukin-11 (rhIL-11)

Purpose To investigate the thrombopoietic effect and the toxicity of injectable recombinant interleukin-11 (rhIL-11) made by domestic pharmacetical company. Methods A randomized,double-blind,placebo-controlled trial was taken to determine the efficacy of rhIL-11. Results The nadir and the day 21 platelet count following chemotherapy increased 57.14% and 103.9% respectively. The persistent days with platelet count lower than normal were significantly shorter in rhIL-11 group than that in placebo-controlled group(P0.001). The average platelet count during the examination period in rhIL-11 group was markedly higher than that in placebo-controlled group. Sever toxicity was not during the trial. Conclusion rhIL-11 is an effective agent thrombocytopenia caused by chemotherapy.